Month: September 2021

Sep 06 2021

Uncategorized

Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia

by Clinical Editor

No Comments

Evenamide has the potential to be the first add-on therapy for patients with positive symptoms of schizophrenia Four-week, double-blind, placebo-controlled study to evaluate safety and efficacy of …

Sep 06 2021

Uncategorized

When Do Schizophrenia Symptoms Start?

by Clinical Editor

No Comments

It’s rare for schizophrenia to appear before 13 or after 40, but it does happen. Here’s when most people develop it and the signs to look out for.

Sep 06 2021

Uncategorized

New treatment option for schizophrenia Reagila(R) listed on PBS

by Clinical Editor

No Comments

A new treatment for schizophrenia in adults, Reagila(R) (cariprazine), was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 Septe …

Sep 06 2021

Uncategorized

Clayton County man suffering from schizophrenia, seizures reported missing

by Clinical Editor

No Comments

Clayton County police are searching for a missing man who suffers from several mental disorders. Donnie Green, 64, suffers from schizophrenia, delirium and has seizures. He was reported missing Sunday...

Sep 05 2021

Uncategorized

When Do Schizophrenia Symptoms Start?

by Clinical Editor

No Comments

It’s rare for schizophrenia to appear before 13 or after 40, but it does happen. Here’s when most people develop it and the signs to look out for.

Sep 05 2021

Uncategorized

What You Need to Know About Prodromal Schizophrenia

by Clinical Editor

No Comments

Prodromal schizophrenia is the earliest stage. The symptoms are more subtle and can appear months or even years before active schizophrenia.

Sep 05 2021

Uncategorized

First and Only Twice-Yearly Treatment for Schizophrenia Receives FDA Approval

by Clinical Editor

No Comments

The one-of-its-kind 6-month paliperidone palmitate treatment for schizophrenia has received FDA approval. The US Food and Drug Administration (FDA) has approved Janssen Pharmaceutical’s long-acting …

Sep 05 2021

Uncategorized

FDA approves twice yearly injection for treatment for adults with schizophrenia

by Clinical Editor

No Comments

USA: The U.S. Food and Drug Administration (FDA) has approved Invega Hafyera (paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults.

Sep 05 2021

Uncategorized

Patients with schizophrenia at different stages show varied deficits in discriminating rewarding values

by Clinical Editor

No Comments

Anhedonia and amotivation are key features of negative symptoms observed in patients with schizophrenia. In particular, amotivation refers to the diminished volition to initiate or maintain …

Sep 04 2021

Uncategorized

Goodbye Schizophrenia – Mad In America – James Moore

by Clinical Editor

No Comments

Goodbye Schizophrenia – Mad In America  James Moore